Effects of eldecalcitol on bone and skeletal muscles in glucocorticoid-treated rats

详细信息    查看全文

• 作者：Hayato Kinoshita ; Naohisa Miyakoshi…
• 关键词：Muscle strength ; Muscle fatigue ; Muscle ; related gene ; Bone ; Eldecalcitol
• 刊名：Journal of Bone and Mineral Metabolism
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：34
• 期：2
• 页码：171-178
• 全文大小：750 KB
• 参考文献：1.da Costa JA, Ribeiro A, Bogas M, Costa L, Varino C, Lucas R, Rodrigues A, Araújo D (2009) Mortality and functional impairment after hip fracture: a prospective study in a Portuguese population. Acta Reumatol Port 34:618–626PubMed
  2.Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001–1005PubMed
  3.Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G (2012) Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 31:652–658CrossRef PubMed
  4.Chan BK, Marshall LM, Winters KM, Faulkner KA, Schwartz AV, Orwoll ES (2007) Incident fall risk and physical activity and physical performance among older men: the Osteoporotic Fractures in Men Study. Am J Epidemiol 165:696–703CrossRef PubMed
  5.Pan HH, Li CY, Chen TJ, Su TP, Wang KY (2014) Association of polypharmacy with fall-related fractures in older Taiwanese people: age- and gender-specific analyses. BMJ Open 4:e004428CrossRef PubMed PubMedCentral
  6.Keller K, Engelhardt M (2014) Strength and muscle mass loss with aging process. Age and strength loss. Muscles Ligaments Tendons J 3:346–350PubMed PubMedCentral
  7.Johnell K, Fastbom J (2008) Multi-dose drug dispensing and inappropriate drug use: a nationwide register-based study of over 700,000 elderly. Scand J Prim Health Care 26:86–91CrossRef PubMed PubMedCentral
  8.Pereira RM, Freire de Carvalho J (2011) Glucocorticoid-induced myopathy. Joint Bone Spine 78:41–44CrossRef PubMed
  9.Larsson L, Sjödin B, Karlsson J (1978) Histochemical and biochemical changes in human skeletal muscle with age in sedentary males, age 22–65 years. Acta Physiol Scand 103:31–39CrossRef PubMed
  10.Schakman O, Gilson H, Thissen JP (2008) Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 197:1–10CrossRef PubMed
  11.Skelton DA, Kennedy J, Rutherford OM (2002) Explosive power and asymmetry in leg muscle function in frequent fallers and non-fallers aged over 65. Age Ageing 31:119–125CrossRef PubMed
  12.Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618–3628CrossRef PubMed
  13.Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of Vitamin D on falls: a meta-analysis. JAMA 291:1999–2006CrossRef PubMed
  14.Dukas L, Schacht E, Mazor Z, Stähelin HB (2005) Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 16:198–203CrossRef PubMed
  15.Kasukawa Y, Miyakoshi N, Maekawa S, Nozaka K, Noguchi H, Shimada Y (2010) Effects of alfacalcidol on muscle strength, muscle fatigue, and bone mineral density in normal and ovariectomized rats. Biomed Res 31:273–279CrossRef PubMed
  16.Miyakoshi N, Sasaki H, Kasukawa Y, Kamo K, Shimada Y (2010) Effects of a vitamin D analog, alfacalcidol, on bone and skeletal muscle in glucocorticoid-treated rats. Bio Med Res 31:329–336
  17.Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures—a randomized, active comparator, double-blind study. Bone (NY) 49:605–612CrossRef
  18.O’Donnell S, Moher D, Thomas K, Hanley DA, Cranney A (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531–542CrossRef PubMed
  19.Nakamura T, Takano T, Fukunaga M, Shiraki M, Matsumoto T (2013) Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. J Bone Miner Metab 31:417–422CrossRef PubMed PubMedCentral
  20.Hagino H, Takano T, Fukunaga M, Shiraki M, Nakamura T, Matsumoto T (2013) Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J Bone Miner Metab 31:183–189CrossRef PubMed PubMedCentral
  21.Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T (2011) Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone (NY) 49:328–334CrossRef
  22.Harada S, Takeda S, Uno A, Takahashi F, Saito H (2010) Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J Steroid Biochem Mol Biol 121:281–283CrossRef PubMed
  23.Sasaki H, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Kamo K, Shimada Y (2009) Muscle strength and fatigue in glucocorticoid-treated rats. Akita J Med 36:195–202
  24.Clarke HH, Shay CT, Mathews DK (1954) Strength decrement of elbow flexor muscles following exhaustive exercise. Arch Phys Med Rehabil 35:560–567PubMed
  25.Murata K, Yano E (2002) Medical statistics for evidence-based medicine with SPBS user’s guide. Nankodo, Tokyo
  26.Compston J (2010) Management of glucocorticoid-induced osteoporosis. J Nat Rev Rheumatol 6:82–88CrossRef
  27.Saito H, Kishimoto K, Okuno H, Tanaka M, Itoi E (2013) Effect of eldecalsitol on C2C12 cell. (in Japanese). Clin Calcium 23:142
  28.Tanaka K, Kanazawa I, Yamaguchi T, Yano S, Kaji H, Sugimoto T (2014) Active vitamin D possesses beneficial effects on the interaction between muscle and bone. Biochem Biophys Res Commun. doi:10.​1016/​j.​bbrc.​2014.​05.​145
  29.Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA (2000) Pax7 is required for the specification of myogenic satellite cells. Cell 102:777–786CrossRef PubMed
  30.Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I, Nabeshima Y (1993) Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature (Lond) 364:532–535CrossRef
  31.Smith CK 2nd, Janney MJ, Allen RE (1994) Temporal expression of myogenic regulatory genes during activation, proliferation, and differentiation of rat skeletal muscle satellite cells. J Cell Physiol 159:379–385CrossRef PubMed
  32.Perez-Ruiz A, Ono Y, Gnocchi VF, Zammit PS (2008) β-Catenin promotes self-renewal of skeletal-muscle satellite cells. J Cell Sci 121:1373–1382CrossRef PubMed
  33.Ceglia L, Rivas DA, Pojednic RM, Price LL, Harris SS, Smith D, Fielding RA, Dawson-Hughes B (2013) Effects of alkali supplementation and vitamin D insufficiency on rat skeletal muscle. Endocrine 44:454–464CrossRef PubMed PubMedCentral
  34.Lieu FK, Powers SK, Herb RA, Criswell D, Martin D, Wood C, Stainsby W, Chen CL (1993) Exercise and glucocorticoid-induced diaphragmatic myopathy. J Appl Physiol 75:763–771PubMed
  35.Dong Y, Pan JS, Zhang L (2013) Myostatin suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS One 8:e58554CrossRef PubMed PubMedCentral
  36.te Pas MF, de Jong PR, Verburg FJ (2000) Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. Mol Biol Rep 27:87–98CrossRef
  37.de Rekeneire N, Visser M, Peila R, Nevitt MC, Cauley JA, Tylavsky FA, Simonsick EM, Harris TB (2003) Is a fall just a fall: correlates of falling in healthy older persons. The Health, Aging and Body Composition Study. J Am Geriatr Soc 51:841–846CrossRef PubMed
  38.Iwamoto J, Sato Y (2014) Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates. Ther Clin Risk Manag 10:51–59CrossRef PubMed PubMedCentral
  
• 作者单位：Hayato Kinoshita (1)
  Naohisa Miyakoshi (1)
  Yuji Kasukawa (1)
  Sadaoki Sakai (2)
  Ayako Shiraishi (3)
  Toyohito Segawa (1)
  Kentaro Ohuchi (1)
  Masashi Fujii (1)
  Chie Sato (1)
  Yoichi Shimada (1)
  
  1. Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan
  2. Product Research Department, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka, 412-8513, Japan
  3. Medical Plan Management Department, Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Metabolic Diseases
  Orthopedics
  Internal Medicine
  
• 出版者：Springer Japan
• ISSN：1435-5604

文摘

Glucocorticoids cause secondary osteoporosis and myopathy, characterized by type II muscle fiber atrophy. We examined whether a new vitamin D₃ analogue, eldecalcitol, could inhibit glucocorticoid-induced osteopenia or myopathy in rats, and also determined the effects of prednisolone (PSL) and/or eldecalcitol on muscle-related gene expression. Six-month-old female Wistar rats were randomized into four groups: PSL group (10 mg/kg PSL); E group (0.05 µg/kg eldecalcitol); PSL + E group; and control group. PSL, eldecalcitol, and vehicles were administered daily for 2 or 4 weeks. Right calf muscle strength, muscle fatigue, cross-sectional areas (CSAs) of left tibialis anterior muscle fibers, and bone mineral density (BMD) were measured following administration. Pax7, MyoD, and myogenin mRNA levels in gastrocnemius muscles were also determined. Muscle strength was significantly higher in the PSL + E group than in the PSL group (p < 0.05) after 4 weeks, but not after 2 weeks. No significant difference in muscle fatigue was seen between groups at 2 or 4 weeks. CSAs of type II muscle fibers were significantly larger in the E group and the PSL + E group than in the PSL group at 4 weeks (p = 0.0093, p = 0.0443, respectively). Eldecalcitol treatment for 4 weeks maintained the same BMD as the PSL + E group. After 2 weeks, but not 4 weeks, eldecalcitol treatment significantly increased Pax7 and myogenin mRNA expression in gastrocnemius muscle, and PSL also stimulated myogenin expression. Eldecalcitol appears to increase muscle volume and to protect against femur BMD loss in PSL-administered rats, and it may also stimulate myoblast differentiation into early myotubes.